FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3164206095> ?p ?o ?g. }

• W3164206095 endingPage "4100" @default.
• W3164206095 startingPage "4089" @default.
• W3164206095 abstract "68Ga-FAPI (fibroblast activation protein inhibitor) is a novel and highly promising radiotracer for PET/CT imaging. The aim of this retrospective analysis is to explore the potential of FAPI-PET/CT in gynecological malignancies. We assessed biodistribution, tumor uptake, and the influence of pre- or postmenopausal status on tracer accumulation in hormone-sensitive organs. Furthermore, a comparison with the current standard oncological tracer 18F-FDG was performed in selected cases.A total of 31 patients (median age 59.5) from two centers with several gynecological tumors (breast cancer; ovarian cancer; cervical cancer; endometrial cancer; leiomyosarcoma of the uterus; tubal cancer) underwent 68Ga-FAPI-PET/CT. Out of 31 patients, 10 received an additional 18F-FDG scan within a median time interval of 12.5 days (range 1-76). Tracer uptake was quantified by standardized uptake values (SUV)max and (SUV)mean, and tumor-to-background ratio (TBR) was calculated (SUVmax tumor/ SUVmean organ). Moreover, a second cohort of 167 female patients with different malignancies was analyzed regarding their FAPI uptake in normal hormone-responsive organs: endometrium (n = 128), ovary (n = 64), and breast (n = 147). These patients were categorized by age as premenopausal (<35 years; n = 12), postmenopausal (>65 years; n = 68), and unknown menstrual status (35-65 years; n = 87), followed by an analysis of FAPI uptake of the pre- and postmenopausal group.In 8 out of 31 patients, the primary tumor was present, and all 31 patients showed lesions suspicious for metastasis (n = 81) demonstrating a high mean SUVmax in both the primary (SUVmax 11.6) and metastatic lesions (SUVmax 9.7). TBR was significantly higher in 68Ga-FAPI compared to 18F-FDG for distant metastases (13.0 vs. 5.7; p = 0.047) and by trend for regional lymph node metastases (31.9 vs 27.3; p = 0.6). Biodistribution of 68Ga-FAPI-PET/CT presented significantly lower uptake or no significant differences in 15 out of 16 organs, compared to 18F-FDG-PET/CT. The highest uptake of all primary lesions was obtained in endometrial carcinomas (mean SUVmax 18.4), followed by cervical carcinomas (mean SUVmax 15.22). In the second cohort, uptake in premenopausal patients differed significantly from postmenopausal patients in endometrium (11.7 vs 3.9; p < 0.0001) and breast (1.8 vs 1.0; p = 0.004), whereas no significant difference concerning ovaries (2.8 vs 1.6; p = 0.141) was observed.Due to high tracer uptake resulting in sharp contrasts in primary and metastatic lesions and higher TBRs than 18F-FDG-PET/CT, 68Ga-FAPI-PET/CT presents a promising imaging method for staging and follow-up of gynecological tumors. The presence or absence of the menstrual cycle seems to correlate with FAPI accumulation in the normal endometrium and breast. This first investigation of FAP ligands in gynecological tumor entities supports clinical application and further research in this field." @default.
• W3164206095 created "2021-06-07" @default.
• W3164206095 creator A5001009180 @default.
• W3164206095 creator A5006080186 @default.
• W3164206095 creator A5008293723 @default.
• W3164206095 creator A5010170241 @default.
• W3164206095 creator A5010632119 @default.
• W3164206095 creator A5014159559 @default.
• W3164206095 creator A5015821667 @default.
• W3164206095 creator A5025369592 @default.
• W3164206095 creator A5029014575 @default.
• W3164206095 creator A5035960100 @default.
• W3164206095 creator A5068074709 @default.
• W3164206095 creator A5072272793 @default.
• W3164206095 creator A5078160124 @default.
• W3164206095 creator A5090973234 @default.
• W3164206095 date "2021-05-29" @default.
• W3164206095 modified "2023-10-11" @default.
• W3164206095 title "68Ga-FAPI-PET/CT in patients with various gynecological malignancies" @default.
• W3164206095 cites W1964818072 @default.
• W3164206095 cites W1997121899 @default.
• W3164206095 cites W2022902107 @default.
• W3164206095 cites W2037825783 @default.
• W3164206095 cites W2042026763 @default.
• W3164206095 cites W2059275990 @default.
• W3164206095 cites W2067213531 @default.
• W3164206095 cites W2077759978 @default.
• W3164206095 cites W2102798237 @default.
• W3164206095 cites W2110615744 @default.
• W3164206095 cites W2138819413 @default.
• W3164206095 cites W2143567791 @default.
• W3164206095 cites W2168002648 @default.
• W3164206095 cites W22020251 @default.
• W3164206095 cites W2347175105 @default.
• W3164206095 cites W2596957190 @default.
• W3164206095 cites W2724454065 @default.
• W3164206095 cites W2786031287 @default.
• W3164206095 cites W2796422399 @default.
• W3164206095 cites W2796437750 @default.
• W3164206095 cites W2807272377 @default.
• W3164206095 cites W2887241162 @default.
• W3164206095 cites W2895852536 @default.
• W3164206095 cites W2930582547 @default.
• W3164206095 cites W2953988494 @default.
• W3164206095 cites W2995884929 @default.
• W3164206095 cites W2999417355 @default.
• W3164206095 cites W3026198184 @default.
• W3164206095 cites W3026934713 @default.
• W3164206095 cites W3037670955 @default.
• W3164206095 cites W3041575745 @default.
• W3164206095 cites W3096784863 @default.
• W3164206095 cites W3109479619 @default.
• W3164206095 cites W3163091095 @default.
• W3164206095 cites W3167710775 @default.
• W3164206095 cites W3180927516 @default.
• W3164206095 cites W628416526 @default.
• W3164206095 cites W95789664 @default.
• W3164206095 doi "https://doi.org/10.1007/s00259-021-05378-0" @default.
• W3164206095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8484099" @default.
• W3164206095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34050777" @default.
• W3164206095 hasPublicationYear "2021" @default.
• W3164206095 type Work @default.
• W3164206095 sameAs 3164206095 @default.
• W3164206095 citedByCount "71" @default.
• W3164206095 countsByYear W31642060952021 @default.
• W3164206095 countsByYear W31642060952022 @default.
• W3164206095 countsByYear W31642060952023 @default.
• W3164206095 crossrefType "journal-article" @default.
• W3164206095 hasAuthorship W3164206095A5001009180 @default.
• W3164206095 hasAuthorship W3164206095A5006080186 @default.
• W3164206095 hasAuthorship W3164206095A5008293723 @default.
• W3164206095 hasAuthorship W3164206095A5010170241 @default.
• W3164206095 hasAuthorship W3164206095A5010632119 @default.
• W3164206095 hasAuthorship W3164206095A5014159559 @default.
• W3164206095 hasAuthorship W3164206095A5015821667 @default.
• W3164206095 hasAuthorship W3164206095A5025369592 @default.
• W3164206095 hasAuthorship W3164206095A5029014575 @default.
• W3164206095 hasAuthorship W3164206095A5035960100 @default.
• W3164206095 hasAuthorship W3164206095A5068074709 @default.
• W3164206095 hasAuthorship W3164206095A5072272793 @default.
• W3164206095 hasAuthorship W3164206095A5078160124 @default.
• W3164206095 hasAuthorship W3164206095A5090973234 @default.
• W3164206095 hasBestOaLocation W31642060951 @default.
• W3164206095 hasConcept C121608353 @default.
• W3164206095 hasConcept C126322002 @default.
• W3164206095 hasConcept C126838900 @default.
• W3164206095 hasConcept C127077266 @default.
• W3164206095 hasConcept C199374082 @default.
• W3164206095 hasConcept C2775842073 @default.
• W3164206095 hasConcept C2777088508 @default.
• W3164206095 hasConcept C2777532014 @default.
• W3164206095 hasConcept C2779066055 @default.
• W3164206095 hasConcept C2779742232 @default.
• W3164206095 hasConcept C2780427987 @default.
• W3164206095 hasConcept C2989005 @default.
• W3164206095 hasConcept C530470458 @default.
• W3164206095 hasConcept C71924100 @default.
• W3164206095 hasConceptScore W3164206095C121608353 @default.

• next